Biowa --- Sorry I don't. That would be useful information.
More generally.....
New Labels for Novantrone, Leukine Drive Twelve Percent Product Sales Increase
SEATTLE, April 16 /PRNewswire/ -- Immunex Corp today reported a net loss for the first quarter of 1997 of $8.7 million, or
22 cents per share, compared to a net loss of $6.2 million, or 16 cents per share, reported in the first quarter of 1996.
Product sales grew 12 percent to $35.9 million in the first three months of 1997, from $32.0 million in the first quarter of 1996.
Overall revenues decreased comparatively due to certain non-recurring contract and license payments that were received in the
first quarter of 1996.
Net sales of NOVANTRONE(R) (mitoxantrone) increased 44 percent to $11.4 million in the first quarter of 1997, compared
to $7.9 million in the same period of 1996. This also exceeded $9.1 million of sales reported in the fourth quarter of 1996.
NOVANTRONE, the company's flagship chemotherapeutic product, was approved late in 1996 for a new use in combination
with corticosteriods to relieve the pain of advanced hormone refractory prostate cancer.
Quarterly net sales of LEUKINE(R) (sargramostim) were $13.0 million, compared to $10.7 million in the first quarter of 1996,
and $10.1 million in the fourth quarter of 1996. In January 1997 the company launched LEUKINE LIQUID, a convenient,
ready-to-use liquid formulation of the white blood cell stimulant.
"We are encouraged by the sales growth of both NOVANTRONE and LEUKINE," said Ed Fritzky, Immunex chairman and
chief executive officer. "We believe that demand for NOVANTRONE increased due to the new indication in advanced
prostate cancer. The new LEUKINE LIQUID formulation has also been well received by our customers. Sales of LEUKINE
may reflect initial stocking of the new formulation by distributors, and we will monitor LEUKINE sales closely over the next
few months to determine the degree to which sustainable demand has increased." |
